Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
Karabajakian A, Bouaoud J, Michon L, Kamal M, Crozes C, Zrounba P, Auclair-Perossier J, Gadot N, Attignon V, Le Tourneau C, Benzerdjeb N, Fayette J, Saintigny P. Karabajakian A, et al. Among authors: zrounba p. Oral Oncol. 2021 Aug;119:105368. doi: 10.1016/j.oraloncology.2021.105368. Epub 2021 Jun 7. Oral Oncol. 2021. PMID: 34111704 Free article.
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Céruse P, Cosmidis A, Belot A, Rabilloud M, Fuchsmann C, Poupart M, Ramade A, Tartas S, Favrel V, Pommier P, Zrounba P, Fayette J. Céruse P, et al. Among authors: zrounba p. Anticancer Drugs. 2014 Sep;25(8):970-5. doi: 10.1097/CAD.0000000000000126. Anticancer Drugs. 2014. PMID: 24849707
Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P. Fayette J, et al. Among authors: zrounba p. Drug Des Devel Ther. 2015 Nov 26;9:6203-10. doi: 10.2147/DDDT.S81488. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26648696 Free PMC article.
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A, Zrounba P, Neidhardt EM, Péron J, Diallo A, Céruse P. Fayette J, et al. Among authors: zrounba p. Oncotarget. 2016 Jun 14;7(24):37297-37304. doi: 10.18632/oncotarget.8934. Oncotarget. 2016. PMID: 27119503 Free PMC article.
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P. Foy JP, et al. Among authors: zrounba p. Ann Oncol. 2017 Aug 1;28(8):1934-1941. doi: 10.1093/annonc/mdx210. Ann Oncol. 2017. PMID: 28460011 Free article.
52 results